# VK2735: Viking Weight Loss Shot and Pill, Phase 3 Results

Source: https://www.dietglp.com/blog/vk2735/
Published: 2026-11-12
Keywords: vk2735, vk2735 phase 3, vk2735 viking, vk2735 trial results, vk2735 clinical trial, vk2735 peptide, vk2735 weight loss, vk2735 side effects, vk2735 vs tirzepatide, vk2735 phase 2 results, vk2735 news, vk2735 fda approval, when will vk2735 be available, vk2735 maintenance dosing study, viking therapeutics vk2735

**TL;DR:** VK2735 is an experimental weight loss drug from Viking Therapeutics that turns on the GLP-1 and GIP receptors, the same two targets as Zepbound. It is being tested as a once-weekly shot and a once-daily pill. It is not FDA-approved and you cannot buy it. In 13-week phase 2 studies, people lost up to 14.7% of their body weight on the shot and up to 12.2% on the pill, and four phase 3 trials are now running, with the first results expected in 2027. Weight that comes off this fast can take muscle with it, so a daily protein target and a short strength workout matter; [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) gives you both.

What is VK2735, and when can you get it? VK2735 is an experimental weight loss drug from Viking Therapeutics. It comes in two forms that are still being tested: a once-weekly shot and a once-daily pill. You cannot get it yet. It is not FDA-approved, and the first phase 3 results are not expected until 2027.

VK2735 is back in the news this week. Viking will show two posters on it at ObesityWeek 2026 in Washington, D.C. (November 14 to 17), and its latest update on October 28, 2026, added new data on taking the shot only once a month. Here is what is known, in plain English.

## VK2735 at a glance

| | VK2735 |
|---|---|
| Maker | Viking Therapeutics (San Diego, Nasdaq: VKTX) |
| Type of drug | Dual GLP-1 and GIP receptor agonist (a peptide) |
| Forms in testing | Once-weekly shot, once-daily tablet |
| Stage | Shot: phase 3 (VANQUISH). Pill: phase 3 started October 2026 (SUNRISE) |
| Best phase 2 result, shot | 14.7% weight loss at 13 weeks |
| Best phase 2 result, pill | 12.2% weight loss at 13 weeks |
| First phase 3 results | Shot trials expected to be completed in 2027 |
| FDA approved? | No |
| Brand name or price | None yet. It is not for sale |

## How VK2735 works: is it a peptide?

Yes. VK2735 is a peptide, a small protein-like drug. It switches on two gut hormone receptors, GLP-1 and GIP. That is the same pair of targets as tirzepatide, sold as Zepbound and Mounjaro. Our guide on [GLP-1 vs GIP](/blog/glp1-vs-gip-explained/) explains what each hormone does.

The unusual part is the pill. Viking put the same peptide into a tablet. Most pills in this class are different drugs from the shots. Foundayo, for example, is a small-molecule drug, not a peptide. Viking says that if its trials succeed, VK2735 could be the first dual GLP-1/GIP pill to reach the market. There is no tirzepatide pill today, as our [Mounjaro pill guide](/blog/mounjaro-pill/) explains.

## VK2735 phase 2 results: the weekly shot

The VENTURE study enrolled 176 adults with obesity, or overweight plus a weight-related health problem. They took a weekly shot for 13 weeks. Viking reported the topline results on February 27, 2024.

| Weekly dose | Average weight loss at 13 weeks | Lost 10% or more |
|---|---|---|
| Placebo | 1.7% | 4% |
| 2.5 mg | 9.1% | 39% |
| 5 mg | 10.9% | 62% |
| 10 mg | 12.9% | 70% |
| 15 mg | 14.7% | 88% |

Viking said weight loss had not leveled off when the study ended. Thirteen weeks is short. Most GLP-1 trials run more than a year.

## VK2735 pill results: the daily tablet

The VENTURE-Oral Dosing study enrolled 280 adults for 13 weeks. Viking reported results on August 19, 2025.

| Daily dose | Average weight loss at 13 weeks | Lost 10% or more |
|---|---|---|
| Placebo | 1.3% | 5% |
| 15 mg | 2.3% | 8% |
| 30 mg | 7.0% | 35% |
| 60 mg | 8.7% | 40% |
| 90 mg | 11.1% | 59% |
| 120 mg | 12.2% | 80% |

The lowest dose, 15 mg, was not clearly better than placebo. More people quit the pill than quit placebo: 28% versus 18% overall, and 20% versus 13% because of side effects.

## VK2735 maintenance dosing study: can you take it once a month?

This is the newest data. In a study of 180 adults with obesity, everyone took a weekly shot (15 mg to 22.5 mg, or placebo) for 21 weeks. Then they switched to a shot every other week, a shot once a month, or placebo, for 12 more weeks.

What Viking reported in its October 28, 2026, update:

- **After 21 weekly shots:** weight loss of about 16% to 19%, versus about 0% on placebo. About 90% of treated people had lost at least 10%.
- **Every-other-week shots:** people kept 83% to 97% of the weight they had lost by week 33.
- **Monthly shots:** people kept 82% to 90%.
- **Switched to placebo:** people kept 61%.
- **Stayed on 17.5 mg weekly for all 33 weeks:** about 22% weight loss, with no plateau seen.

In simple words, spacing the shots out held most of the loss over 12 weeks. That is a short window, and the groups were small (11 groups shared 180 people). A second part of the study, with about 195 adults, is testing a switch from the weekly shot to the daily pill. Viking expects those results in 2027. Amgen is chasing the same monthly idea with [MariTide](/blog/maritide/).

## VK2735 side effects

Stomach problems lead the list, as with every drug in this class.

| Side effect | Shot study: VK2735 vs placebo | Pill study: VK2735 vs placebo |
|---|---|---|
| Nausea | 43% vs 20% | 58% vs 48% |
| Vomiting | 18% vs 0% | 26% vs 10% |
| Diarrhea | 20% vs 9% | Not in the summary we read |
| Constipation | 26% vs 11% | Not in the summary we read |

Viking described most side effects as mild or moderate. One serious case of dehydration in the shot study was judged related to the drug. These are small, short studies. Rare risks only show up in large, long trials, which is what phase 3 is for.

Fast weight loss has one more cost that side effect tables miss: muscle. In trials of approved GLP-1 drugs, a meaningful share of the weight lost was lean mass. Viking has not published body composition data for VK2735 that we could find. The safe habit is the same on any of these drugs: eat enough protein and do strength work. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) gives you one protein target and one 20-minute workout a day, so the weight you lose is mostly fat. Our guide on [how much protein you need](/blog/protein-target-on-glp1/) shows the math.

## VK2735 phase 3 trials: VANQUISH and SUNRISE

| Trial | Form | Who | Size | Length | Doses |
|---|---|---|---|---|---|
| VANQUISH-1 | Weekly shot | Adults with obesity | About 4,500 | 78 weeks | 7.5, 12.5, 17.5 mg |
| VANQUISH-2 | Weekly shot | Adults with obesity or overweight and type 2 diabetes | About 1,000 | 78 weeks | 7.5, 12.5, 17.5 mg |
| SUNRISE-1 | Daily pill | Adults with obesity or overweight | 560 planned | 68 weeks | 27.5, 35, 55 mg |
| SUNRISE-2 | Daily pill | Adults with obesity or overweight and type 2 diabetes | 560 planned | 68 weeks | 27.5, 35, 55 mg |

Both VANQUISH trials are fully enrolled. Viking says it expects them to be completed in 2027. Extension studies, which will test every-other-week and monthly shots for up to 52 more weeks, are due to begin in early 2027, with results in 2028.

The pill trials were started in October 2026. On November 12, 2026, ClinicalTrials.gov listed both as not yet recruiting.

## VK2735 vs tirzepatide (Zepbound)

They hit the same two receptors, but they have never been tested head to head. The trial lengths are also very different, so the numbers below cannot be compared directly.

| | VK2735 | Tirzepatide (Zepbound) |
|---|---|---|
| Targets | GLP-1 and GIP | GLP-1 and GIP |
| Status | Phase 3, not approved | FDA-approved |
| Key weight loss result | 14.7% at 13 weeks (phase 2, top dose) | 20.9% at 72 weeks (SURMOUNT-1, 15 mg) |
| How often | Weekly shot; monthly being tested | Weekly shot |
| Pill version | In phase 3 | None |

The honest answer on which is stronger: nobody knows yet. The 78-week VANQUISH results will be the first fair look. For the approved options today, see our [GLP-1 drugs list](/blog/glp-1-drugs-list/) and our [semaglutide vs tirzepatide](/blog/semaglutide-vs-tirzepatide/) comparison.

## VK2735 FDA approval date: when will it be available?

There is no approval date and no filing date. The rough path looks like this:

1. **2027:** VANQUISH-1 and VANQUISH-2 expected to be completed.
2. **After that:** Viking would need to file with the FDA. It has not said when.
3. **FDA review:** a standard review usually takes about 10 to 12 months after filing.

So the shot is unlikely to reach pharmacies before 2028, and that only happens if the trials succeed. The pill is at least a year behind the shot.

## Can you buy VK2735 now?

No. Real VK2735 only exists inside Viking's clinical trials. Websites that sell "VK2735" as a research peptide are selling an unapproved product with no proof of what is in the vial. The FDA has warned many times about unapproved GLP-1 products sold online. If you want a dual GLP-1/GIP drug today, the approved one is tirzepatide, and that is a conversation for your prescriber.

## What this means for you

- **If you are on a GLP-1 now:** nothing changes. VK2735 is years from a pharmacy shelf.
- **If you are waiting for a pill:** approved pills already exist. See our [GLP-1 pill vs shot](/blog/glp-1-pill-vs-shot/) guide.
- **If the monthly shot idea appeals to you:** it is promising but early. The real test is the 52-week extension data due in 2028.
- **Whatever you take:** the drug handles appetite. Protein and strength training protect your muscle. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) tracks both with one daily Shape Score, so you can see you are losing fat, not muscle.

## Sources

- [Viking Therapeutics: Third Quarter 2026 Financial Results and Corporate Update (October 28, 2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)
- [Viking Therapeutics: Phase 2 VENTURE top-line results (February 27, 2024)](https://ir.vikingtherapeutics.com/2024-02-27-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Patients-with-Obesity)
- [Viking Therapeutics: Phase 2 VENTURE-Oral Dosing top-line results (August 19, 2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)
- [Viking Therapeutics: Initiation of VK2735 oral phase 3 program (October 14, 2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)
- [Viking Therapeutics: Two poster presentations at ObesityWeek 2026 (November 9, 2026)](https://ir.vikingtherapeutics.com/2026-11-09-Viking-Therapeutics-Announces-Two-Poster-Presentations-at-ObesityWeek-R-2026)
- [ClinicalTrials.gov: VANQUISH-1 (NCT07104500)](https://clinicaltrials.gov/study/NCT07104500)
- [ClinicalTrials.gov: VANQUISH-2 (NCT07104383)](https://clinicaltrials.gov/study/NCT07104383)
- [ClinicalTrials.gov: SUNRISE-1 (NCT07868835)](https://clinicaltrials.gov/study/NCT07868835)
- [Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)


## Frequently asked questions

**Q: What is VK2735?**

A: VK2735 is an investigational dual GLP-1 and GIP receptor agonist made by Viking Therapeutics, a San Diego biotech company. It is being studied for obesity as a once-weekly injection and as a once-daily tablet. It has no brand name or generic name yet.

**Q: Is VK2735 FDA approved?**

A: No. As of November 12, 2026, VK2735 is in phase 3 trials and has not been submitted to the FDA. Viking expects its two injection trials to be completed in 2027. The company has not announced a filing date or an approval date.

**Q: When will VK2735 be available?**

A: There is no release date. The phase 3 injection trials (VANQUISH-1 and VANQUISH-2) run 78 weeks and are expected to finish in 2027. After that come the FDA filing and review. The pill is further behind: its phase 3 trials were only started in October 2026.

**Q: Is VK2735 a peptide or a small molecule?**

A: VK2735 is a peptide, like tirzepatide and semaglutide. The pill is a tablet form of the same peptide used in the shot. It is not a small-molecule pill like Foundayo (orforglipron).

**Q: How much weight do people lose on VK2735?**

A: In the 13-week phase 2 VENTURE study, average weight loss was 14.7% on the top weekly shot dose versus 1.7% on placebo. In the 13-week pill study, it was 12.2% on the top dose versus 1.3% on placebo. In a newer 33-week study, a group kept on 17.5 mg weekly lost about 22%. These are company topline numbers.

**Q: What are the side effects of VK2735?**

A: Mostly stomach problems. In the phase 2 shot study, nausea was reported by 43% of people on VK2735 versus 20% on placebo, constipation by 26% versus 11%, diarrhea by 20% versus 9% and vomiting by 18% versus 0%. Viking says most cases were mild or moderate.

**Q: Can I buy VK2735 or join a clinical trial?**

A: You cannot buy real VK2735. Anything sold online under that name is unapproved and unverified. The injection phase 3 trials are full. The pill trials, SUNRISE-1 and SUNRISE-2, were listed as not yet recruiting on ClinicalTrials.gov on November 12, 2026.

